CTMX stock forecast
Our latest prediction for CytomX Therapeutics, Inc.'s stock price was made on the Sept. 4, 2018 when the stock price was at 22.23$.
In the short term (2weeks), CTMX's stock price should outperform the market by 0.73%. During that period the price should oscillate between -6.70% and +7.56%.
In the medium term (3months), CTMX's stock price should underperform the market by -0.52%. During that period the price should oscillate between -16.09% and +20.97%.
Get email alertsAbout CytomX Therapeutics, Inc.
CytomX Therapeutics, Inc. engages in the development of antibody therapeutics for the treatment of cancer based on its Probody therapeutic technology platform. Its pipeline includes immunotherapies, probody drug conjugates, T cell engaging bispecifics, and other multiple programs. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.
At the moment the company generates 75M USD in revenues.
On its last earning announcement, the company reported a loss of -1.26$ per share.
The book value per share is 0.91$
Three months stock forecastSept. 4, 2018
Financials
| Revenue USD | Gross Margin | Operating Income | Operating Margin | Net Income | Earnings Per Share | Dividends | Payout Ratio | Shares | Book Value Per Share | Operating Cash Flow | Cap Spending | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 75M | - | -53M | -71.00% | -52M | -1.26 | - | - | 40M | 0.91 | -25M | -3M | -28M |